A two-drug combination for metastatic melanoma reduced the odds of progression by 60 percent, demonstrating more effectiveness than monotherapy, according to researchers.
LC-OCT Demonstrates Potential For Rapid, Effective Visualization of Inflammatory Conditions Across Skin Types
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
From Earth to Skin: Reviewing the Role of Environmental Factors in Dermatologic Conditions
ReV Up Your Vitiligo Treatment Strategies
European Union Approves Bimekizumab to Treat HS
ICYMI: US FDA Recently Approves Stelara Biosimilar Ustekinumab-aekn for Psoriasis, Psoriatic Arthritis